Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valuing the Johnson & Johnson spin-off at about $48.7 billion in enterprise value. Kenvue holders are set to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, equal to $21.01 per share based on October 31 pricing, a 46% premium to Kenvue’s prior close.… The post Kimberly-Clark’s $48.7B Kenvue bet is to pay a premium amid Tylenol noise appeared first on Drug Discovery and Development.| Drug Discovery and Development
Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration… The post 2025 pharma M&A surges to $70 billion in major deals appeared first on Drug Discovery and De...| Drug Discovery and Development